Clinicopathological Features of Lupus Nephritis Patients in North-East India; A Single Center Retrospective Observational Study
Main Article Content
Keywords
clinicopathological presentation, histopathology, lupus nephritis, systemic lupus erythematosus
Abstract
Clinicopathological presentation of lupus nephritis (LN) patients varies with different race and ethinicity of the population. Only few studies describe clinicopathological spectrum of LN patients in the Indian population. The aim of this study was to determine the clinicopathological spectrum of LN in the North-East Indian population. This was a retrospective observational study that included patients with LN at a tertiary care center in North-East India from March 2007 to August 2018. Clinical and histopathological data at the time of presentation were collected from hospital records. Renal biopsies were examined by light microscopy and direct immunofluorescence techniques. A total of 340 patients of LN were included in this study. The mean age of presentation was 22.42 ± 4.3 years. The minimum age at presentation was 8 years and 18.8% belonged to the <18 year age group. The present study showed a male:female ratio of 1:8. The majority of patients were of class IV (71.9%). Arthralgia (47.1%) and anemia (60.3%) were the most common presenting symptom and sign, respectively. Immunoglobulin (Ig) G was the most abundant immunoglobulin (positive in 98.47%) and the least positive was IgA (positive in 41.18%). Complement (C) 3 and C1q were positive in all. Full house deposition was found in 59.3% of the biopsies. The rates of hypertension, microscopic hematuria, renal dysfunction, and nephrotic syndrome were 43.5, 59.12, 45.9, and 35.3%, respectively. Patients of LN in the North-East Indian population present at an earlier age with a more severe form of the disease (class IV) at the time of presentation.
References
2. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, Vollenhoven RV, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2: 16039. doi:10.1038/nrdp.2016.39
3. Tang Y, Zhang W, Zhu M, Zheng L, Xie L, Yao Z, et al. Lupus nephritis pathology prediction with clinical indices. Scientific Reports. 2018 Jul 6;8(1): 1–8. 10.1038/s41598-018-28611-7
4. Croca SC, Rodrigues T, Isenberg DA.: Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011; 50: 1424–1430. 10.1093/rheumatology/ker101
5. Ward MM.: Changes in the incidence of end-stage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009; 36: 63–67. 10.3899/jrheum.080625
6. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: Aa retrospective analysis. Am J Med. 2002;112: 726–9. 10.1016/S0002-9343(02)01118-X
7. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005;14: 265–72. 10.1191/0961203305lu2081oa
8. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15(2): 241–50. 10.1097/01.ASN.0000108969.21691.5D
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematous. Arthritis Rheum. 1997; 40(9): 1725. 10.1002/art.1780400928
10. Hachiya A, Karasawa M, Imaizumi T, Kato N, Katsuno T, Ishimoto T, et al. The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis. Scientific Reports. 2021 Jan 15;11(1): 1–2. 10.1038/s41598-020-78972-1
11. Austin HA, III, Boumaps DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994; 45: 544–550. 10.1038/ki.1994.70
12. Yu F, Tan Y, Wu LH, Zhu SN, Liu G, Zhao MH. Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus. 2009;18: 1073. 10.1177/0961203309106795
13. Alba V, Lucia S, Cristina C, Giovanni MF, Sandra L, Alessandro NC, et al. Lupus nephritis: the value of biochemical and immunological monitoring of disease activity. Ren Fail. 1996;18: 755–763. 10.3109/08860229609047704
14. Baqui MN, Akhter S, Kabir E, Islam MS. A clinicopathological study on lupus nephritis; experience of 34 cases from Bangladesh. J Nephropharmacol. 2016; 5(1): 19–23.
15. Gun HC, Yoon KH, Fong KY. Clinical outcomes of patients with biopsy-proven lupus nephritis in NUH. Singapore Med J. 2002;43: 614–16.
16. Zheng H, Chen Y, Ao W, Shen Y, Chen X, Dai M, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther. 2009;11(3): 93. 10.1186/ar2736
17. Nezhad ST, Sepaskhah R. Correlation of clinical and pathological findings in patients with lupus nephritis: a five year experience in Iran. Saudi Journal of Kidney Disease and Transplantation. 2008;19: 32–40.
18. Donadio JV, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995;4: 109–15. 10.1177/096120339500400206
19. Hill GS, Delahousse M, Nochy D, Tomkiewicz E, Rémy P, Mignon F, Gary SH, Michel D, Dominique N, Elizabeth T, Philippe RM, Franc, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int. 2000;58: 1160–73. 10.1046/j.1523-1755.2000.00272.x
20. Ong C, Nicholls K, Becker G. Ethnicity and lupus nephritis: an Australian single centre study. Intern Med J. 2011;41: 270–8. 10.1111/j.1445-5994.2009.02159.x
21. Patel M, Clarke AM, Bruce IN, Symmons D. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Eevidence of an ethnic gradient. Arthritis Rheum. 2006 Sep; 54(9): 2963–9. 10.1002/art.22079
22. Rabbani MA, Memon GM, Ahmad B, Memon S, Tahir SA, Tahir S. Percutaneous renal biopsy results: a retrospective analysis of 511 consecutive cases. Saudi J Kidney Dis Transpl. 2012 May; 23(3): 614–18.
23. Kosaraju K, Shenoy S, Suchithra U. A cross-sectional hospital based study of autoantibody profile and clinical manifestation of systemic lupus erythematosus in South Indian patients. Indian J Med Microbiol. 2010;28: 245–7. 10.4103/0255-0857.66487
24. Srivastava P, Abujam B, Misra R, Lawrence A, Agarwal V, Aggarwal A. Outcome of lupus nephritis in childhood onset SLE in North and Central India: single-centre experience over 25 years. Lupus. 2016 Apr;25(5): 547–57. 10.1177/0961203315619031
25. Nossent H, Berden J, Swaak T. Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis. Lupus. 2000;9: 504–10. 10.1177/096120330000900705
26. Das R, Saleh A, Kabir A, Talukder SI, Kamal M. Immunofluorescence studies of renal biopsies. Dinajpur Med Col J. 2008;1: 8–13.
27. Salem Almaani S, AlexaMeara A, Brad H. Rovin BH. Update on Llupus Nnephritis. CJASN. May 2017;,12(5): 825–835. 10.2215/CJN.05780616
28. Davidson A. What is damaging the kidney in lupus nephritis?. Nature Reviews Rheumatology. 2016 Mar 12(3): 143–53. 10.1038/nrrheum.2015.159
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.